

sotatercept powder and solvent for solution for injection (Winrevair®)

SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2831	in combination with other pulmonary arterial hypertension (PAH) therapies, for the treatment of PAH in adult patients with WHO Functional Class (FC) II to III, to improve exercise capacity.	Not routinely available as not recommended for use in NHS Scotland	09/02/2026	21/01/2026
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9785/sotatercept-winrevair-final-jan-2026-for-website.pdf				

zuranolone hard capsule (Zurzuvae®)

SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2862	treatment of moderate or severe postnatal depression (PND) in adults following childbirth.	Not routinely available as not recommended for use in NHS Scotland	09/02/2026	21/01/2026
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9786/zuranolone-zurzuvae-final-jan-2026-for-website.pdf				

donanemab concentrate for solution for infusion (Kisunla®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2871	for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease (AD) in adult patients that are apolipoprotein E ε4 (ApoE ε4) heterozygotes or non-carriers.	Not routinely available as not recommended for use in NHS Scotland	09/02/2026	21/01/2026
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9787/donanemab-kisunla-final-jan-2026-for-website.pdf				